Platform utilizes combinatorial engineering and automation to screen in high-throughput, generating capsids greatly improved over AAV9 in CNS efficiency and specificity. Process development and manufacturing data validate in-house capability to produce highly productive and scalable processes up to 200L.
Preclinical results demonstrate proof-of-concept of early generation AAV-engineered capsid in MPSII pilot program. Data from capsid engineering platform show greater than 100-fold improvement over AAV9 across both infants and juveniles. Top capsid variants show broad protein expression across the primate CNS.
Dr. Nick Goeden and Dr. Nick Flytzanis – “the Nicks,” as many of their colleagues call them – have a lot in common. They’re both co-founders and leaders at Capsida Biotherapeutics. They’re both 35 years old. And, this month, they were both named to the 2022 Endpoints “20 Under 40” list. This annual honor, selected … Read More
Company creates chief operating officer role and appoints veteran manufacturing and supply-chain executive Rayne Waller to help Capsida capitalize on its platform gene therapy technology, bringing treatments to patients with debilitating and life-threatening genetic disorders Mr. Waller will retain responsibility for manufacturing in addition to other operational functions Company’s proprietary technology allows for targeted non-invasive … Read More
Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality Anastasiou’s key to leadership stands at the intersection of what’s right for patients and business. As the CEO of Capsida Biotherapeutics, Peter Anastasiou is optimistic — no, let’s make that excited — that the company’s novel and proprietary next-generation adeno-associated virus (AAV) platform … Read More
THOUSAND OAKS, Calif., December 9, 2021 — Capsida Biotherapeutics, Inc., an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders, today announced research published in Nature Neuroscience that demonstrated the ability to engineer and select novel capsid variants, with improved enrichment in … Read More
Longtime industry executive Peter Anastasiou appointed Chief Executive Officer Capsida co-founders Nicholas Flytzanis, Ph.D., promoted to Chief Scientific Officer and Nick Goeden, Ph.D., promoted to Chief Technology Officer Company’s proprietary technology allows for targeted non-invasive gene therapy for the brain and body, while limiting collateral impact on non-targeted areas THOUSAND OAKS, Calif., December 7, 2021 … Read More
Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, is pleased to announce that co-founder and vice president of Technology Nick Goeden, PhD, and Swati Tole, MD MS, will speak at the Gene Therapy for Neurological Disorders … Read More
New 15,000 square-foot facility in Thousand Oaks will enable industry leading end-to-end gene therapy manufacturing capability THOUSAND OAKS, Calif., July 22, 2021 – Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, today announced the opening of … Read More
Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases ZUG, Switzerland, CAMBRIDGE, Mass., and THOUSAND OAKS, Calif. – June 15, 2021 — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Capsida Biotherapeutics Inc., a biotechnology company dedicated to developing … Read More